Filtered By:
Specialty: International Medicine & Public Health
Drug: Aspirin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
ConclusionsFor stroke prevention in AF, direct OACs seem to be more effective and safer than usual care, and apixaban (5 mg twice daily) had the best profile. For VTE, there was no strong evidence that direct OACs were better than usual care. Education and pharmacist management could improve coagulation control. Both clinicians and patients rated efficacy and safety as the most important factors in managing AF and V TE.Systematic review registrationPROSPERO CRD42017084263 —one deviation; efficacy and safety were from one review.
Source: Systematic Reviews - October 28, 2022 Category: International Medicine & Public Health Source Type: research
EE165 Cost-Effectiveness Analysis Model of Aspirin and Aspirin Combination Therapy in Acute Ischemic Stroke Patient in West Sumatera
Aspirin usage as monotherapy in acute ischemic stroke has been well-documented as the therapeutic option for early stroke management and recurrent stroke prevention. Recent studies have shown the potential of aspirin combination (dual antiplatelet therapy with clopidogrel) in effectively decreasing the possibility of recurrent stroke. Despite the promising clinical effectiveness, a cost-effectiveness model was built to compare these two options.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: N Fitria, F Putrizeti, YO Sari Source Type: research
Low ‑dose Aspirin for Primary Prevention of Cardiovascular Events in Postmenopausal Women with Type‑2 Diabetes: The Prescriptive Approach in the Real World
Conclusions: Low ‑dose aspirin in our population is prescribed preferentially in postmenopausal women with type‑2 diabetes when affected by metabolic syndrome or metabolic cardiomyopathy, at the opposite women with only high risk have lower chance to receive aspirin.
Source: International Journal of Preventive Medicine - January 2, 2022 Category: International Medicine & Public Health Source Type: research
Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - August 19, 2021 Category: International Medicine & Public Health Source Type: research
PCV22 Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA
The efficacy of ticagrelor 90mg and aspirin (ticagrelor-aspirin) for the prevention of stroke following an ischaemic stroke (IS) or transient ischaemic attack (TIA) was evaluated in the Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death (THALES, NCT03354429) trial. Ticagrelor-aspirin resulted in a 17% reduction in the risk of stroke or death over 30 days versus aspirin, but with more bleeding events. Ticagrelor 90mg is approved to reduce stroke risk in patients with acute IS (NIH Stroke Scale score ≤5) or high-risk TIA by the Food and Drug Administration.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. McEwan, O. Darlington, M. Knutsson, H. Denison, P. Ladenvall, P. Amarenco, S.C. Johnston, S. Evans, S. James, A. Himmelmann, J. Venditto, C. Mellstrom, N. Atreja, A. Tank Source Type: research
Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - April 8, 2021 Category: International Medicine & Public Health Source Type: research
Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study
ConclusionsAmong an urban-dwelling population of adults, the use of secondary prevention of CVD was low, with lower aspirin and combination GDMT for Black participants with CAD. Efforts to improve GDMT use at the patient and provider levels may be needed to improve morbidity and mortality and reduce disparities in CVD.
Source: Journal of Racial and Ethnic Health Disparities - February 16, 2021 Category: International Medicine & Public Health Source Type: research
Newer blood thinner plus aspirin reduced stroke risk by 27% in patients with heart plaque
(American Heart Association) Patients who suffered a 'warning stroke' were less likely to have another stroke or die within 30 days if treated with a combination of aspirin and a newer blood thinner, ticagrelor. Researchers say that for patients with minor stroke treated within 24 hours of symptom onset, clinicians should consider the combination of ticagrelor plus aspirin to prevent a subsequent stroke.
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news
Ticagrelor alone, without aspirin, shows benefit in patients with diabetes
(American College of Cardiology) Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year. The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news
Aspirin's health benefits under scrutiny
(University of Georgia) Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven't already experienced one of these events.
Source: EurekAlert! - Medicine and Health - December 9, 2019 Category: International Medicine & Public Health Source Type: news
Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study
Publication date: Available online 30 August 2019Source: The Lancet Global HealthAuthor(s): John K Lin, Andrew E Moran, Kirsten Bibbins-Domingo, Bode Falase, Andrea Pedroza Tobias, Charuta N Mandke, Dhruv S KaziSummaryBackgroundFewer than 25% of patients with atherosclerotic cardiovascular disease in countries of low and middle income (LMICs) use guideline-directed drugs for secondary prevention. A fixed-dose combination polypill might improve cardiovascular outcomes by increasing prescription rates and adherence, but the cost-effectiveness of this approach is uncertain.MethodsWe developed microsimulation models to assess ...
Source: The Lancet Global Health - September 1, 2019 Category: International Medicine & Public Health Source Type: research
Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
Conclusions:Novel oral anticoagulants (NOACs) seem to be a better choice as a pharmacological therapy in the treatment of AF, due to a lack of adequate monitoring of patients ’ international normalized ratio (INR) values. CHA2DS2‑VASc and HASBLED scores must be used as a part of routine clinical diagnostics when dealing with patients with AF.Keywords:Atrial fbrillation, hemorrhage, risk, stroke, therapeutics
Source: International Journal of Preventive Medicine - June 3, 2019 Category: International Medicine & Public Health Source Type: research
Stopping aspirin three months after stenting does not increase risk of death
(American College of Cardiology) Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12 inhibitor -- clopidogrel, prasugrel or ticagrelor -- did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding.
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news
Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
(American Heart Association) The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients.
Source: EurekAlert! - Medicine and Health - February 6, 2019 Category: International Medicine & Public Health Source Type: news
Aspirin may lower stroke risk in women with history of preeclampsia
(Columbia University Irving Medical Center) A new study by Columbia researchers suggests aspirin may lower stroke risk among middle-aged women with a history of preeclampsia.
Source: EurekAlert! - Medicine and Health - January 22, 2019 Category: International Medicine & Public Health Source Type: news
